Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Core Insights - Palvella Therapeutics, Inc. is hosting a conference call on February 24, 2026, to discuss topline results from the Phase 3 SELVA clinical trial for QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations [1] Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations without FDA-approved treatments [3] - The company is developing a pipeline of product candidates based on its patented QTORIN™ platform, with QTORIN™ 3.9% rapamycin anhydrous gel as the lead candidate for microcystic lymphatic malformations and other conditions [3] - A second product candidate, QTORIN™ pitavastatin, is being developed for the topical treatment of disseminated superficial actinic porokeratosis [3] Conference Call Details - The conference call will take place at 8:00am ET, with a press release on topline results expected at approximately 6:30am ET [1] - Access to the live webcast and call details can be found on Palvella's website [2]